论文部分内容阅读
目的:探讨O6-甲基鸟嘌呤-DNA甲基转移酶(O6-methylguanine-DNA methyltransferase,MG-MT)在甲状腺癌组织中的表达及其临床意义。方法:用免疫组织化学SP法检测61例甲状腺癌、21例甲状腺良性腺瘤、15例桥本氏甲状腺炎、8例结节性甲状腺肿和12例癌旁正常组织中MGMT蛋白的表达,并结合临床病理因素进行分析。结果:MGMT在甲状腺癌组织中的表达与正常组织中的表达差异有统计学意义(P<0.05)。MGMT表达从正常组织(16.67%,10/12)、结节性甲状腺肿(25.00%,2/8)、桥本氏甲状腺炎(60.00%,9/15)、甲状腺腺瘤(52.38%,11/21)到甲状腺癌(60.66%,38/61)中表达水平基本呈上升趋势。在甲状腺乳头状癌与甲状腺滤泡癌的表达差异有统计学意义(P<0.05),表达水平随甲状腺癌恶性程度的增加而降低,分别为乳头状癌(72.22%,26/36)、滤泡癌(50.00%,8/16)。MGMT在性别、年龄及民族组中表达差异均无统计学意义(P>0.05)。结论:MGMT高表达现象可能与甲状腺癌恶性程度有关,可成为候选的临床分子诊断指标。甲状腺癌组织的MGMT蛋白在性别、年龄和民族组表达均无差异,有望成为通用的临床检测指标。
Objective: To investigate the expression of O6-methylguanine-DNA methyltransferase (MG-MT) in thyroid carcinoma and its clinical significance. Methods: The expressions of MGMT protein in 61 cases of thyroid cancer, 21 cases of thyroid benign adenoma, 15 cases of Hashimoto’s thyroiditis, 8 cases of nodular goiter and 12 cases of normal tissues were detected by immunohistochemical SP method. Combined with clinical and pathological factors were analyzed. Results: The expression of MGMT in thyroid cancer tissues was significantly different from that in normal tissues (P <0.05). MGMT expression was significantly higher in normal tissues (16.67%, 10/12), nodular goiter (25.00%, 2/8), Hashimoto’s thyroiditis (60.00%, 9/15), thyroid adenoma (52.38%, 11 / 21) to thyroid cancer (60.66%, 38/61), the expression level is basically on the rise. There was a significant difference in the expression of thyroid papillary carcinoma and thyroid follicular carcinoma (P <0.05). The expression of thyroid carcinoma decreased with the increase of the malignant degree of thyroid carcinoma (72.22%, 26/36) Bubble cancer (50.00%, 8/16). There was no significant difference in MGMT expression between sex, age and ethnic group (P> 0.05). Conclusion: The high expression of MGMT may be related to the degree of malignancy of thyroid cancer and may be a candidate clinical molecular diagnostic indicator. MGMT protein in thyroid cancer showed no difference in sex, age and ethnic group, which is expected to become a universal clinical detection index.